Fulcrum Therapeutics Stock Price, News & Analysis

Fulcrum Therapeutics (NASDAQ: FULC) announced upcoming presentations at two major medical conferences: the 5th Global Congress on Sickle Cell Disease in Abuja, Nigeria (June 3-6, 2025) and the 2025 European Hematology Association Congress in Milan, Italy (June 12-15, 2025).

The company will present four posters focusing on Pociredir, their novel oral treatment for Sickle Cell Disease (SCD). The presentations will cover preclinical and early clinical results, Phase 1b trial design, pharmacokinetics and pharmacodynamics in healthy adults, and the drug's mechanism as an EED inhibitor for fetal hemoglobin induction.

Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in the 46th Annual Goldman Sachs Global Healthcare Conference. The company's management will engage in a fireside chat on June 11, 2025, at 8:00 am ET in Miami, FL. The presentation will be available via webcast on the company's investor relations website, with replay access for at least 30 days following the event.

Fulcrum Therapeutics (NASDAQ: FULC) has granted stock options to two new employees as part of their inducement compensation package. The grants, made under the company's 2022 Inducement Stock Incentive Plan, include a total of 260,000 options to purchase common stock at an exercise price of $5.73 per share, matching the closing price on May 5, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters. Vesting is contingent on continued employment with Fulcrum through the applicable dates.

Fulcrum Therapeutics (NASDAQ: FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has announced its participation in two upcoming investor conferences in May 2025:

1. The H.C. Wainwright BioConnect Investor Conference at NASDAQ in New York on May 20, 2025

2. The RBC Capital Markets Global Healthcare Conference in New York on May 21, 2025, featuring a fireside chat at 3:35 pm ET

The fireside chat webcast will be available on Fulcrum's investor relations website and will remain accessible for at least 30 days after the presentation.

Fulcrum Therapeutics (NASDAQ: FULC) reported Q1 2025 financial results and business updates. The company completed enrollment in the 12 mg dose cohort (n=16) of the Phase 1b PIONEER trial for pociredir in sickle cell disease and initiated the 20 mg dose cohort. Clinical data is expected in early Q3 2025 for the 12 mg cohort and by end of 2025 for the 20 mg cohort. The trial shows >90% drug adherence with no discontinuations. Financial highlights include: $226.6 million in cash/equivalents (vs $241.0M in Q4 2024), reduced R&D expenses of $13.4 million (vs $19.8M in Q1 2024), lower G&A expenses of $7.0 million (vs $10.1M in Q1 2024), and net loss of $17.7 million (vs $26.9M in Q1 2024). The company expects its current cash position to fund operations into at least 2027.

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company specializing in small molecule development for rare genetic diseases, has scheduled its first quarter 2025 financial results release for Thursday, May 1, 2025, before U.S. market opening.

The company will host a conference call and webcast at 8:00 a.m. ET where management will present the quarterly results and provide corporate development updates. Participants can access the call through a registration link that will provide dial-in details and a unique PIN. The webcast will be available through the company's Investor Relations website.

Fulcrum Therapeutics (FULC), a clinical-stage biopharmaceutical company focused on developing small molecules for rare genetic diseases, has granted stock options to two new employees under its 2022 Inducement Stock Incentive Plan. The grants, announced on April 11, 2025, include an aggregate of 96,800 options with an exercise price of $2.72 per share, matching the closing price on April 7, 2025.

The options have a ten-year term and follow a four-year vesting schedule: 25% vests on the first employment anniversary, followed by 6.25% vesting quarterly over the next twelve quarters, contingent on continued employment.

Fulcrum Therapeutics (Nasdaq: FULC), a clinical-stage biopharmaceutical company developing small molecules for rare genetic diseases, has announced its participation in the Leerink Partners Global Healthcare Conference. The company's management will engage in a fireside chat on March 11, 2025 at 8:40 am ET in Miami, FL.

The presentation will be accessible via webcast through the company's website investor relations section and will remain available for replay for a minimum of 30 days following the event.

Fulcrum Therapeutics (Nasdaq: FULC) reported its Q4 and full year 2024 financial results, highlighting progress in its lead program, pociredir for sickle cell disease (SCD). The company has enrolled 10 patients in the 12 mg dose cohort of the Phase 1b PIONEER trial and expects to share clinical data from this cohort in mid-2025 and from the 20 mg dose cohort by year-end.

Financial highlights include $241.0 million in cash, cash equivalents, and marketable securities as of December 31, 2024, providing runway into at least 2027. Full-year 2024 collaboration revenue was $80.0 million, primarily from a Sanofi upfront payment. R&D expenses decreased to $63.4 million for 2024 (from $71.8 million in 2023), while G&A expenses fell to $36.4 million (from $41.7 million). Net loss for 2024 was $9.7 million, significantly reduced from $97.3 million in 2023.

Fulcrum also plans to submit an IND for Diamond-Blackfan anemia in Q4 2025 and will present data from its discontinued losmapimod program at the 2025 MDA Conference in March.